PRTK earnings call for the period ending December 31, 2018.
News & Analysis: Paratek Pharmaceuticals
Find out which of these companies is looking for a buyer.
The pharma company announced a debt offering that has Wall Street scrambling.
Shares dive after the antibiotic drug developer announces the pricing details of a secondary common stock offering.
Paratek Corp., Nabriva Therapeutics, and Cempra all appear on course to bring new antibiotics to market soon. But which could be the best bet for your portfolio now?
The roller-coaster ride continues for this clinical-stage biotech's stock.
Shares soar after the company reports upbeat data from a pivotal clinical trial.
The antibiotic developer is interested in cashing out.
Jounce Therapeutics, Lexicon Pharmaceuticals, and Paratek Pharmaceuticals might be three hidden gems in the healthcare sector worth checking out.
The company announced first-quarter 2017 earnings and provided a clinical update.